Zobrazeno 1 - 10 of 487 pro vyhledávání: '"Bothe U"'
1
Akademický článek
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839 .
Autor: Bothe U; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Günther J; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Nubbemeyer R; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Siebeneicher H; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Ring S; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Bömer U; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Peters M; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Rausch A; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Denner K; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Himmel H; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Sutter A; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Terebesi I; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Lange M; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Wengner AM; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Guimond N; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Thaler T; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Platzek J; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Eberspächer U; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Schäfer M; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Steuber H; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Zollner TM; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Steinmeyer A; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany., Schmidt N; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 1225-1242. Date of Electronic Publication: 2024 Jan 16.
Zobrazit plný text záznamu
2
Akademický článek
Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor.
Autor: Langer G; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.) stefan.baeurle@bayer.com gernot.langer@bayer.com., Scott J; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Lind C; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Otto C; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Bothe U; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Laux-Biehlmann A; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Müller J; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., le Roy B; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Irlbacher H; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Nowak-Reppel K; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Schlüter A; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Davenport AJ; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Slack M; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Bäurle S; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.) stefan.baeurle@bayer.com gernot.langer@bayer.com.
Publikováno v: Molecular pharmacology [Mol Pharmacol] 2023 Sep; Vol. 104 (3), pp. 105-114. Date of Electronic Publication: 2023 Jun 22.
Zobrazit plný text záznamu
3
Akademický článek
Discovery of BAY-390 , a Selective CNS Penetrant Chemical Probe as Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonist.
Autor: Mesch S; Pharmaceutical R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Walter D; Discovery Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K., Laux-Biehlmann A; Exploratory Pathobiology, RED preMED, R&D, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Basting D; Pharmaceutical R&D, Drug Discovery, Lead Identification and Characterization, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Flanagan S; Discovery Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K., Miyatake Ondozabal H; Pharmaceutical R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Bäurle S; Pharmaceutical R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Pearson C; Discovery Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K., Jenkins J; Discovery Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K., Elves P; Discovery Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K., Hess S; In Vitro Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany., Coelho AM; In Vivo Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany., Rotgeri A; Pharmaceutical R&D, Early Development, Drug Metabolism and Pharmacokinetics, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Bothe U; Pharmaceutical R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Nawaz S; In Vivo Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany., Zollner TM; Pharmaceutical R&D, Preclinical Research, Therapeutic Area Endocrinology, Metabolism and Reproductive Health, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany., Steinmeyer A; Pharmaceutical R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2023 Jan 26; Vol. 66 (2), pp. 1583-1600. Date of Electronic Publication: 2023 Jan 09.
Zobrazit plný text záznamu
4
Novel carboranes with a DNA binding unit for the treatment of cancer by boron neutron capture therapy
Autor: Tietze, LF, Griesbach, U, Bothe, U, Nakamura, Hiroyuki, Yamamoto, Y
Publikováno v: ChemBioChem. 3:219-225
The synthesis and biological evaluation of two ortho-carborane derivatives which contain a 5,6,7-trimethoxyindole (TMI) unit for use in boron neutron capture therapy is described. The TMI moiety is known to be the DNA-binding part of the highly poten
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9a26924cc975fe1ec6c2665f34747d
https://doi.org/10.1002/1439-7633(20020301)3:2/3<219::aid-cbic219>3.0.co
Zobrazit plný text záznamu
5
ortho-Carboranyl Glycosides for the Treatment of Cancer by Boron Neutron Capture Therapy
Autor: Tietze, LF, Bothe, U, Griesbach, U, Nakaichi, M, Hasegawa, T, Nakamura, Hiroyuki, Yamamoto, Y
Publikováno v: Bioorganic & Medicinal Chemistry. 9:1747-1752
Distinct biological properties of the ortho-carboranyl (1,2-dicarba-closo-dodecaboranyl) glycosides 1, 2 and 3 were evaluated to estimate the suitability of these compounds for cancer treatment by boron neutron capture therapy. The boron uptake into
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74af7499118717533432662de6479771
https://doi.org/10.1016/s0968-0896(01)00061-x
Zobrazit plný text záznamu
7
Akademický článek
Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis.
Autor: Bäurle S; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Nagel J; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Peters O; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Bräuer N; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Ter Laak A; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Preusse C; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Rottmann A; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Heldmann D; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Bothe U; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Blume T; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Zorn L; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Walter D; Evotec (UK) Ltd. , 112-114 Innovation Drive , Milton Park, Abingdon , Oxfordshire OX14 4RZ , U.K., Zollner TM; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Steinmeyer A; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany., Langer G; Bayer AG, Research & Development, Pharmaceuticals , Müllerstrasse 178 , 13353 Berlin , Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2019 Mar 14; Vol. 62 (5), pp. 2541-2563. Date of Electronic Publication: 2019 Feb 22.
Zobrazit plný text záznamu
8
Akademický článek
Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
Autor: Islam I; Medical Core Facility and Research Platforms, King Abdullah International Medical Research Center/King Saud Bin, Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States. Electronic address: imadulislam@yahoo.com., Yuan S; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., West CW; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Adler M; Department of Biophysics, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Bothe U; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States; Research and Development Pharmaceutical, Bayer AG, 13342 Berlin, Germany., Bryant J; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Chang Z; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Chu K; Department of Molecular Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Emayan K; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Gualtieri G; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Ho E; Department of Animal Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Light D; Department of Antibody Technology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Mallari C; Department of Animal Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Morser J; Cardiovascular Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Phillips G; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Schaefer C; Department of Animal Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Sukovich D; Department of Molecular Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Whitlow M; Department of Biophysics, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Chen D; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States., Buckman BO; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Nov 01; Vol. 28 (20), pp. 3372-3375. Date of Electronic Publication: 2018 Sep 05.
Zobrazit plný text záznamu
9
Akademický článek
The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.
Autor: Jodl, Stefan J.1 (AUTHOR) stefan.jodl@bayer.com, ten Voorde, Wouter2,3 (AUTHOR), Klein, Stefan1 (AUTHOR), Wagenfeld, Andrea1 (AUTHOR), Zollmann, Frank S.4 (AUTHOR), Feldmüller, Maximilian1 (AUTHOR), Klarenbeek, Naomi B.2 (AUTHOR), de Bruin, Digna T.2 (AUTHOR), Jansen, Manon A. A.2 (AUTHOR), Rissmann, Robert2,5 (AUTHOR), Rohde, Beate1 (AUTHOR), Moerland, Matthijs2,3 (AUTHOR) mmoerland@chdr.nl
Publikováno v: CTS: Clinical & Translational Science. Mar2024, Vol. 17 Issue 3, p1-14. 14p.
Zobrazit plný text záznamu
10
Akademický článek
Metal Rich Metallaboranes: Synthesis, Structure and Bonding of pileo -[(Cp*Ru) 2 M(CO) 3 (µ -H)(µ -E)(µ 3 -BH)B 2 H 5 ] (M = Mo, W, E = CO, and M = Mn, E = H) Clusters.
Autor: Pradhan, Alaka Nanda1 (AUTHOR) salupradhan7@gmail.com, Jaiswal, Shippy1 (AUTHOR) jaiswalshippy167@gmail.com, Cordier, Marie2 (AUTHOR) marie.dallon@univ-rennes.fr, Halet, Jean-François2,3 (AUTHOR) jean-francois.halet@univ-rennes.fr, Ghosh, Sundargopal1 (AUTHOR) jean-francois.halet@univ-rennes.fr
Publikováno v: Inorganics. Jan2024, Vol. 12 Issue 1, p7. 13p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje